VEGF inhibitors for anti-angiogenic therapy / Kari Alitalo.

Format:

Video

Author/Creator:

Alitalo, Kari, author.

Series:

Henry Stewart talks

Language:

English

Subjects (All):

Neovascularization inhibitors.

Physical Description:

1 streaming video file (1 hour, 11 min., 03 sec.) : sound, color.

Place of Publication:

London : Henry Stewart Talks Ltd, 2007.

System Details:

video file

Summary:

Audio-visual presentation : Antagonist monoclonal antibodies to VEGFR-3 ; Mode of action of antagonist monoclonal antibodies ; Functional properties of antagonist antibodies to VEGFR-3 ; In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis ; Inhibition of pathological vessel growth in the cornea ; Anti-angiogenic effect of antibodies to VEGFR-3 in tumors ; Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 ; Role of VEGFR-3 in normal and pathological immune response.

Contents:

Introduction

Angiogenesis-VEGF

Angiogenesis-VEGF-C/D

VEGF and VEGFR tyrosine kinase

Strategies to inhibit VEGFR signaling

MuMAb VEGF A4.6.1

RhuMAb VEGF-Avastin

Blocking Ab differ from other agents

Anti-VEGF Ab prevents VEGF/VEGFR interaction

Potential effects of inhibiting VEGF

Anti-angiogenesis 'normalises' tumour vasculature

Anti-VEGF Ab modifies tumor vasculature

VEGF inhibition can induce capillary regression

Ranibizumab

Pegaptanib

'Metronomic' anti-angiogenic chemotherapy

Preclinical models

Potential effects of anti-VEGF therapy

Anti-VEGFR2 mAb

Treatment of human xenograft tumors with DC101

VEGFR-2 blockade

VEGFR-2 block leads to increase in tumor hypoxia

Anti-VEGFR-2 mAb and gemcitabine

VEGFR-2 Ab IMC-1121b

Structure and properties of VEGF trap

Angiogenesis inhibitors in clinical trials

Conclusions (1)

Conclusions (2)

Inhibitors of lymphangiogenesis

Tumor lymphangiogenesis and metastasis

VEGF-C/D trap prevents VEGFR-3 signaling

VEGF-C/D trap prevents lymph vessels growth

Inhibition of lymphangiogenesis with VEGFR-3-Fc

Blocking metastasis to lymph nodes

Model of lymphatic metastasis

Model of prevention of lymphatic metastasis

Proteolytic processing of VEGF-C/D

VEGF in hematogenous and lymphatic spread

Antagonist monoclonal Abs to VEGFR-3

Soluble receptors (traps) and antagonist antibodies

Antagonist monoclonal antibodies to VEGFR-3

Mode of action of antagonist mAbs to RTKs

Functional properties of alpha-VEGFR-3 mAbs

Dermal lymphatic regeneration model in mouse

Systemic alpha-VEGFR-3 treatment

Angio- and lymphangiogenesis blocking

Alpha-VEGFR-3 inhibits growth of carcinomas

Alpha-VEGFR-3 inhibits metastasis of carcinoma

VEGF-C induces hypertrophy of lymphatic vessels

Alpha-VEGFR-3 inhibits lymph vessels hypertrophy

Alpha-VEGFR-3 reduces metastasis to lymph

The role of VEGFR-3 in inflammation

Expansion of the lymphatic network

Prevention of lymphatic hyperplasia

Alpha-VEGFR-3 modulates adaptive immunity

VEGF-C, VEGFR-3 and inflammation (1)

VEGF-C, VEGFR-3 and inflammation (2)

Rejection of renal transplants

Conclusions (3).

Notes:

Description based on publisher supplied metadata and other sources.

Retrieved April 12, 2024, from https://hstalks.com/bs/465/.